Construction method of T cell strain highly expressing PD-1
*The invention discloses a construction method of a T cell strain highly expressing PD-1, and relates to the technical field of cell engineering, the technical key points are as follows: S1, lentivirus construction and packaging; s2, virus infection: S2-1, virus dissolution; s2-2, paving a plate by using a 6-pore plate, performing 1000RPM3 minutes according to 1 * 10 * 5 cells/well, and taking cell precipitates; the virus and the cells in the step S2-1 are precipitated and resuspended, contrast is established at the same time, and culture is carried out under the conditions of 37 DEG C and 5% CO2; s2-3, after culturing for 12-24 hours in the step S2-2, centrifuging to remove virus liquid after cell infection, adding 2mL of complete culture liquid, and continuously culturing for 48 hours at the temperature of 37 DEG C and 5% CO2; s3, screening stably transferred plants; S3-1, carrying out a pre-experiment; and S3-2, screening of stably transferred plants. According to the method disclosed by the invention, a T cell strain model for highly expressing PD-1 is innovatively constructed, and the dual effects of tumor targeting and immune checkpoint blocking can be realized by utilizing the natural affinity of PD-1 on the surface of a T cell membrane to PD-L1 of tumor cells, so that tumor targeting delivery of antitumor drugs is realized..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 12. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHU LINGLING [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-12, Last update posted on www.tib.eu: 2023-12-12, Last updated: 2023-12-15 |
|---|
| Patentnummer: |
CN116732102 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018759076 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018759076 | ||
| 003 | DE-627 | ||
| 005 | 20231215095752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231215s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018759076 | ||
| 035 | |a (EPA)CN116732102 | ||
| 035 | |a (EPA)87903490 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHU LINGLING |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Construction method of T cell strain highly expressing PD-1 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-12, Last update posted on www.tib.eu: 2023-12-12, Last updated: 2023-12-15 | ||
| 520 | |a *The invention discloses a construction method of a T cell strain highly expressing PD-1, and relates to the technical field of cell engineering, the technical key points are as follows: S1, lentivirus construction and packaging; s2, virus infection: S2-1, virus dissolution; s2-2, paving a plate by using a 6-pore plate, performing 1000RPM3 minutes according to 1 * 10 * 5 cells/well, and taking cell precipitates; the virus and the cells in the step S2-1 are precipitated and resuspended, contrast is established at the same time, and culture is carried out under the conditions of 37 DEG C and 5% CO2; s2-3, after culturing for 12-24 hours in the step S2-2, centrifuging to remove virus liquid after cell infection, adding 2mL of complete culture liquid, and continuously culturing for 48 hours at the temperature of 37 DEG C and 5% CO2; s3, screening stably transferred plants; S3-1, carrying out a pre-experiment; and S3-2, screening of stably transferred plants. According to the method disclosed by the invention, a T cell strain model for highly expressing PD-1 is innovatively constructed, and the dual effects of tumor targeting and immune checkpoint blocking can be realized by utilizing the natural affinity of PD-1 on the surface of a T cell membrane to PD-L1 of tumor cells, so that tumor targeting delivery of antitumor drugs is realized. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHOU QINGHUA |4 aut | |
| 700 | 0 | |a FAN MINGYU |4 aut | |
| 700 | 0 | |a HUANG WEIJIA |4 aut | |
| 700 | 0 | |a YEO HYUN CHUL |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 12. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:12 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87903490/publication/CN116732102A1?q=CN116732102 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 12 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 12 |c 09 | ||